Patients with blood group O have a lower risk of lymph node metastases but a higher risk of bilateral disease.
Patients aged 75-79 who had localized tumors had worse cancer-specific survival with nonsurgical management than surgery.
Patients with this malignancy had a 73% prevalence of simple renal cysts.
Only 9.5% of the study participants were told about the possibilities of overdiagnosis and overtreatment by their physicians.
Most want to be told of screening harms, but only 9.5 percent informed about overdiagnosis, overtx.
Recurrence that occurs more than 48 months after surgery is no longer significantly associated with reduced survival from renal cell carcinoma.
A phase 3 trial has found pazopanib (Votrient) and sunitinib (Sutent) are both equally effective for treating metastatic kidney cancer.
Researchers observe a high rate of local disease control with increased progression-free survival.
It improves predictions of perioperative complication risks, according to researchers.
In a head-to-head trial, patients had similar progression-free survival with pazopanib and sunitinib, but experienced fewer adverse effects.
Renal cancers were found in 5% of patients with autosomal dominant polycystic kidney disease.
The beneficial impact of this approach on renal function does not improve survival, however.
Recent studies provide persuasive evidence that the majority of small renal masses will grow slowly over time.
Dr. Crispen highlights the advantages and challenges of active surveillance for small renal masses.
Highest intake found to increase the risk of renal pelvis and ureter cancers 11-fold.
Robotic-assisted kidney cancer surgery appears to be associated with more "excessive" hospital charges.
Bone metastases shorten progression-free and overall survival, study finds.
The vow never to treat SRMs may seem hard to believe and self-defeating.
Compared with radical nephrectomy, nephron-sparing surgery shift serum creatinine downward.
Study demonstrates improved disease-specific and overall survival.
Male gender and older age found to be significantly associated with chronic kidney disease before and surgery.
New findings have implications for preoperative patient counseling.
Study finds a 1.6 times increased risk, but no association with complications after radical cystectomy or prostatectomy.
Hispanics are 20% less likely to undergo the procedure than whites.
The harms of nephrectomy, however, need to be weighed against the marginal survival benefit for some patients.
Cancer-specific and the cancer-free survival rates were 99% at three and five years.
Risk is threefold greater when compared with partial nephrectomy.
A new immunoassay appears to be a valid screening method for the early detection of kidney cancer.
It is associated with a high technical success rate and a low rate of complications; local recurrence rare.
After a median follow-up of 36 months, 98% of patients had no recurrence of small renal tumors.